Search Results - "Van Doorn, M.B.A"

MK-0873, a PDE4 inhibitor, does not influence the pharmacokinetics of theophylline in healthy male volunteers by Boot, J.D, De Haas, S.L, Van Gerven, J.M.A, De Smet, M, Leathem, T, Wagner, J, Denker, A, Miller, D, Van Doorn, M.B.A, Schoemaker, R.C, Cohen, A.F, Diamant, Z

“…Abstract Background MK-0873 is a novel selective phosphodiesterase-4 inhibitor, which has been in development for the treatment of chronic obstructive…”
Get full text

Recurrence rate of lentigo maligna after micrographically controlled staged surgical excision by de Vries, K., Greveling, K., Prens, L.M., Munte, K., Koljenović, S., van Doorn, M.B.A., Prens, E.P.

“…Summary Background Lentigo maligna is a slowly growing melanoma in situ. Current guidelines advise wide local excision with a margin of 5 mm as the treatment…”
Get full text

Mobile e‐diary application facilitates the monitoring of patient‐reported outcomes and a high treatment adherence for clinical trials in dermatology by Rijsbergen, M., Niemeyer‐van der Kolk, T., Rijneveld, R., Pinckaers, J.H.F.M., Meshcheriakov, I., Bouwes Bavinck, J.N., van Doorn, M.B.A., Hogendoorn, G., Feiss, G., Cohen, A.F., Burggraaf, J., van Poelgeest, M.I.E., Rissmann, R.

“…Background Assessment of treatment effects in clinical trials requires valid information on treatment adherence, adverse events and symptoms. Paper‐based…”
Get full text

Clinical relevance of immunogenicity of biologics in psoriasis: Implications for treatment strategies by Carrascosa, J.-M., van Doorn, M.B.A., Lahfa, M., Nestle, F.O., Jullien, D., Prinz, J.C.

“…Biological drugs such as the tumour necrosis factor inhibitors have revolutionized the treatment of psoriasis, but some have the potential to induce an…”
Get full text

A two-stage treatment of lentigo maligna using ablative laser therapy followed by imiquimod: excellent cosmesis, but frequent recurrences on the nose by Greveling, K., de Vries, K., van Doorn, M.B.A., Prens, E.P.

Get full text

Apremilast for moderate hidradenitis suppurativa: no significant change in lesional skin inflammatory biomarkers by Vossen, A.R.J.V., van der Zee, H.H., Davelaar, N., Mus, A.M.C., van Doorn, M.B.A., Prens, E.P.

“…Background Treatment with apremilast has recently demonstrated clinically meaningful improvement in moderate hidradenitis suppurativa (HS). Objective To…”
Get full text

Non‐invasive anaesthetic methods for dermatological laser procedures: a systematic review by Greveling, K., Prens, E.P., Liu, L., Doorn, M.B.A.

“…Pain is a common side‐effect of dermatological laser procedures. Non‐invasive anaesthetic drugs and anaesthetic procedures can be used to provide pain relief…”
Get full text

Age and fast initial response predict omalizumab retreatment in chronic urticaria by Meertens, M.A.J., Luijf, T., van Lindonk, E.A.M., Soegiharto, Reineke, Assil, S., Aghdam, M. Alizadeh, Kentie, P.A., Knulst, A.C., van Doorn, M.B.A., Röckmann, H.

Get full text

Lentigo maligna – anatomic location as a potential risk factor for recurrences after non‐surgical treatment by Greveling, K., Klok, Th, Doorn, M.B.A., Noordhoek Hegt, V., Prens, E.P.

“…Background A higher incidence of lentigo maligna (LM) recurrences on the nose was previously observed in our cohort after non‐surgical treatment. Objectives To…”
Get full text

Combining biologics with methotrexate in psoriasis: a systematic review by van Bezooijen, J.S., Prens, E.P., Pradeepti, M.S., Atiqi, R., Schreurs, M.W.J., Koch, B.C.P., van Gelder, T., van Doorn, M.B.A.

Get full text

A fistula in disguise- a case report by Smit, P., Wiryasaputra, D.C.M.S., van Doorn, M.B.A.

Get full text

Pharmacokinetic differences between Caucasian and Japanese subjects after single and multiple doses of a potential combined oral contraceptive (Org 30659 and EE) by de Visser, S.J., Uchida, N., van Vliet-Daskalopoulou, E., Fukazawa, I., van Doorn, M.B.A., van den Heuvel, M.W., Machielsen, C.S.M., Uchida, E., Cohen, A.F.

“…To compare the pharmacokinetic parameters and safety of the progestagen, Org 30659, (17α)-17-hydroxy-11-methylene-19-norpregna-4,15-dien-20-yn-3-one), and…”
Get full text